Literature DB >> 17594327

Clinical characteristics and course of spinal cord involvement in Behçet's disease.

N Yesilot1, M Mutlu, O Gungor, B Baykal, P Serdaroglu, G Akman-Demir.   

Abstract

Parenchymal neurological involvement in Behçet's disease (p-NBD) usually presents with a brainstem syndrome; occasionally spinal cord may also be involved. Files of patients with Behçet's disease and spinal cord involvement were reviewed retrospectively, in comparison with other types of p-NBD. Amongst 216 patients with p-NBD, 24 had spinal cord involvement (11%). Most commonly patients presented with sensory-motor symptoms, sphincter and/or sexual dysfunction evolving over days. Four of 10 patients showed single or multiple cervical and/or dorsal lesions on spinal MRI's and one showed dorsal atrophy. Although the clinical picture was variable, it tended to be severe; seven cases had primary progressive course, 11 cases had a secondary progressive course after initial attack(s), four had attacks with severe residual sequela and two had improvement after attacks. After a median follow-up period of 67 months, eight were independent and 14 were dead or dependent, whereas amongst the remaining patients with p-NBD, 113 patients were independent and 56 patients were dead or dependent (P < 0.05). Our study suggests that spinal cord involvement has even worse prognosis compared with other types of p-NBD. Therefore, recognition of spinal cord involvement in Behçet's patients should prompt early vigorous treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17594327     DOI: 10.1111/j.1468-1331.2007.01754.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  20 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Behçet's Disease.

Authors:  Gulsen Akman-Demir; Sabahattin Saip; Aksel Siva
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

4.  Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab.

Authors:  Uğur Uygunoğlu; Maarya Pasha; Sabahattin Saip; Aksel Siva
Journal:  J Spinal Cord Med       Date:  2014-03-28       Impact factor: 1.985

Review 5.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

6.  Behcet's disease presenting with sudden-onset paraplegia due to anterior spinal artery involvement: 1-year follow-up of rehabilitation in conjunction with medication.

Authors:  Iltekin Duman; Umut Guzelkucuk; Kutay Tezel; Koray Aydemir; Bilge Yılmaz
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 7.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

8.  Association of amyotrophic lateral sclerosis and Behcet's disease: is there a relationship? A multi-national case series.

Authors:  Hela Mrabet; Afshin Borhani-Haghighi; Emel Koseoglu; Melike Mutlu; Recep Baydemir; Shahriar Nafissi; Slim Eschebbi; Emel Delibas; Shahdokht Samangooie; Fatih Yetkin; Amel Mrabet; Yesim Parman; Seyed Taghi Heydari; Gulsen Akman-Demir
Journal:  Clin Rheumatol       Date:  2012-01-11       Impact factor: 2.980

Review 9.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

10.  Treatment of myelitis in Behçet's disease with rituximab.

Authors:  Maria Josè Messina; Mariaemma Rodegher; Roberta Scotti; Vittorio Martinelli
Journal:  BMJ Case Rep       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.